When to visit the vet?
Non-urgent see a veterinarian within 2–3 days
If the condition worsens / symptoms persist, consult a veterinarian.
Definition
Glioblastomas and astrocytomas are types of brain tumors in dogs that originate from glial cells, the support cells in the nervous system. These tumors are malignant and tend to grow rapidly and behave aggressively.
The most important facts at a glance
Glioblastomas and astrocytomas are primary brain tumors in dogs that originate directly in the brain. They develop from astrocytes, a type of glial cell. These tumors primarily occur in older dogs and vary in their aggressiveness. The exact causes are not fully understood, but genetic factors and environmental factors could play a role. Certain breeds such as Boxers and French Bulldogs are more susceptible, indicating a genetic predisposition. Symptoms include neurological problems such as seizures, Disorientation, and Behavioral changes. Diagnosis is usually made through imaging techniques such as MRI or CT, and in some cases, a biopsy is necessary. Treatment is challenging and often includes surgical intervention, radiation therapy, and in some cases, chemotherapy. The prognosis is usually unfavorable because the tumors are aggressive. Survival time can be extended with treatment, but relapses are common. There are no specific prevention measures, but general health promotion can reduce the risk. Research focuses on genetic analyses and new therapy approaches to develop better treatment options for both dogs and humans.
Causes
Glioblastomas and astrocytomas are primary brain tumors, meaning they originate directly in the brain and do not metastasize there from other parts of the body. They arise from astrocytes, a type of glial cell that plays a supportive role for neurons in the brain. These tumors are particularly common in older dogs and vary in their aggressiveness and growth rate.
The exact cause of glioblastomas and astrocytomas in dogs is not fully understood, but genetic factors play a significant role. It is believed that mutations in certain genes that regulate cell growth can lead to uncontrolled cell division of astrocytes. Environmental factors such as exposure to certain chemicals or radiation could also play a role, but this has not yet been definitively clarified.
Certain breeds appear to be more susceptible to developing these tumors, including Boxers, Boston Terriers, and French Bulldogs. This suggests that there is a genetic predisposition that could increase the risk of brain tumors in these dog breeds. However, research in this area is still ongoing to further identify the exact causes and risk factors.
Symptoms
The symptoms of glioblastomas and astrocytomas in dogs vary depending on the location and size of the tumor. The most common signs are neurological in nature, as the tumor directly affects brain tissue. These include seizures, which can increase in intensity and frequency. These seizures are often the first sign that alerts the owner.
Other symptoms may include Behavioral changes, such as apathy, Aggressiveness, or Confusion. Dogs may also have difficulty orienting themselves, and changes in gait may occur. Motor problems such as Paralysis or weakness on one side of the body are also possible.
Depending on the location of the tumor, specific symptoms may also occur, such as visual or Hearing loss, if the tumor is near the corresponding brain regions. In advanced stages, increased intracranial pressure can occur, leading to Vomiting, headaches (which may manifest as head pressing or shaking), and disturbances of consciousness.
Therapy
The treatment of glioblastomas and astrocytomas in dogs is challenging and depends on factors such as the location and size of the tumor, as well as the dog’s general health. Surgical intervention is often the first choice to remove as much tumor tissue as possible. However, complete resections are often not possible because the tumors usually grow into sensitive brain regions.
Radiation therapy can be used in conjunction with surgery to kill remaining tumor cells and further control tumor growth. This is particularly helpful for tumors that cannot be completely removed surgically. Chemotherapy is also occasionally used, but its effectiveness in brain tumors is limited because many drugs cannot effectively cross the blood-brain barrier.
Symptomatic treatment is also important to improve the dog’s quality of life. This may include administering anticonvulsants to control seizures and anti-inflammatory drugs to reduce cerebral edema. Pain relievers may also be prescribed to support the animal’s well-being.
Prognosis and follow-up care
The prognosis for glioblastomas and astrocytomas is often unfavorable because these tumors are malignant and aggressive. Even with intensive treatment, survival time is usually limited. Without treatment, the average survival time is often only a few months.
With surgical intervention and radiation therapy, survival time can be extended, often to about one year, depending on the dog’s individual response to treatment. However, the disease is ultimately progressive, and relapses are common.
Quality of life plays a central role in treatment decision-making. Owners often have to make a difficult trade-off between extending life and maintaining an acceptable quality of life, especially when the side effects of treatment are significant.
Prevention
Since the exact causes of glioblastomas and astrocytomas in dogs are not fully known, there are no specific preventive measures that can guarantee prevention of the disease. The genetic predisposition in certain breeds makes it difficult to completely eliminate the risk.
However, general measures to promote the dog’s health can help minimize the risk. These include a balanced diet, regular veterinary check-ups, and avoiding exposure to known carcinogens. Early detection of symptoms and prompt action if neurological problems are suspected can also help improve treatment outcomes.
Research in the field of brain tumors in dogs is progressing, and there is hope that future insights will enable more effective prevention strategies and treatment approaches. Until then, education and vigilance on the part of pet owners are the best protection they can offer their four-legged friends.
Outlook on current research
Research into glioblastomas and astrocytomas in dogs has made significant progress in recent years. These tumors are particularly aggressive and pose a challenge for treatment. They resemble human glioblastomas in many ways, making them a valuable model for studying this disease. Scientists are using this similarity to develop new treatment methods that could be applied to both dogs and humans. One focus of research is the genetic analysis of these tumors to better understand which genetic mutations lead to their development.
A significant advance is the application of personalized medicine approaches based on the genetic profiles of the tumors. By analyzing genetic mutations in tumor tissue, researchers can identify specific drugs that target these mutations. These approaches promise to increase treatment effectiveness and reduce side effects. Furthermore, research is being conducted on how immunotherapies, which stimulate the body’s immune system to fight tumors, can be used in dogs.
Another area of research is the development of imaging techniques for better diagnosis and monitoring of brain tumors. Advances in magnetic resonance imaging (MRI) and positron emission tomography (PET) make it possible to detect tumors earlier and assess the response to therapies more accurately. These technologies are crucial for evaluating the effectiveness of new treatment approaches and improving the prognosis for affected dogs.
Research into the application of radiation therapy and chemotherapy is also being intensified. New radiation therapy techniques that are more precise and spare healthy tissues are being developed to improve the quality of life for dogs. In addition, combination therapies are being tested, in which different treatment approaches are combined to combat tumors more effectively. These multidisciplinary approaches require the collaboration of veterinarians, oncologists, and researchers from various disciplines.
Collaboration between veterinary and human medicine is crucial to leverage synergies and facilitate the transfer of research findings from animals to humans. Clinical studies conducted in both dogs and humans offer the opportunity to develop and validate new therapies more quickly. These studies are an important part of translational research, which aims to translate scientific findings into practical applications.
In summary, research into glioblastomas and astrocytomas in dogs continues intensively to develop new treatment options and improve the prognosis for affected animals. Advances in genetic analysis, personalized medicine, imaging techniques, and therapy approaches offer promising prospects for the future.
Frequently Asked Questions (FAQs)
1. What are glioblastomas and astrocytomas in dogs?
2. How are these tumors diagnosed?
3. What Symptoms occur in affected dogs?
4. What Treatment Options are Available?
5. What is the prognosis for dogs with these tumors?
6. Are there risk factors for the development of these tumors?
7. Can these tumors be prevented?
8. What role does nutrition play in treatment?
9. Are these tumors similar in humans?
10. Are there new developments in treatment?
Literature
- Stoica, G., Levine, J., Wolff, J., & Murphy, K. (2011). Canine astrocytic tumors: A comparative review. Veterinary Pathology, 48(1), 266–275. https://doi.org/10.1177/0300985810389543
- Koehler, J. W., Miller, A. D., Miller, C. R., Porter, B., Aldape, K., Beck, J., Brat, D. J., Cornax, I., Corps, K., Frank, C., Giannini, C., Horbinski, C., Huse, J. T., O’Sullivan, M. G., Rissi, D. R., Rossmeisl, J. H., Sims, M. H., Stoica, G., Woolard, K. D., … LeBlanc, A. K. (2018). A revised diagnostic classification of canine glioma: Towards validation of the canine glioma patient as a naturally occurring preclinical model for human glioma. Journal of Neuropathology & Experimental Neurology, 77(11), 1039–1054. https://doi.org/10.1093/jnen/nly085
- José-López, R., Gutierrez-Quintana, R., de la Fuente, C., Manzanilla, E. G., Suñol, A., Pi Castro, D., Añor, S., Sánchez-Masian, D., Fernández-Flores, F., Ricci, E., Marioni-Henry, K., Mascort, J., Matiasek, L. A., Matiasek, K., Brennan, P. M., & Pumarola, M. (2021). Clinical features, diagnosis, and survival analysis of dogs with glioma. Journal of Veterinary Internal Medicine, 35(4), 1902–1917. https://doi.org/10.1111/jvim.16199
- Merickel, J. L., Pluhar, G. E., Rendahl, A., & O’Sullivan, M. G. (2021). Prognostic histopathologic features of canine glial tumors. Veterinary Pathology, 58(5), 945–951. https://doi.org/10.1177/03009858211025795
- Rossmeisl, J. H., Clapp, K., Pancotto, T. E., Emch, S., Robertson, J. L., & Debinski, W. (2016). Canine butterfly glioblastomas: A neuroradiological review. Frontiers in Veterinary Science, 3, 40. https://doi.org/10.3389/fvets.2016.00040
- Demeter, E. A., Frank, C. B., & Koehler, J. W. (2019). Microtubule-associated protein 2 expression in canine gliomas. Frontiers in Veterinary Science, 6, 395. https://doi.org/10.3389/fvets.2019.00395
- José-López, R. (2023). Chemotherapy for the treatment of intracranial glioma in dogs. Frontiers in Veterinary Science, 10, 1273122. https://doi.org/10.3389/fvets.2023.1273122
- dos Santos, E. C., Rissi, D. R., et al. (2024). Canine glioma in the first year of life: 5 cases. Veterinary Pathology, 61(4), 617–623. https://doi.org/10.1177/03009858241244913